Management of High Grade Bladder Cancer: A Multidisciplinary Approach, An Issue of Urologic Clinics
Arjun Balar
· ISBN 9780323376242
Special offer terms
Zookal Study Premium
Subscribe & save
By selecting the 'Susbcribe & Save' option you are enrolling in an auto-renewing subscription of Zookal Study Premium. Cancel at anytime.
Auto-Renewal
Your Zookal Study Premium subscription will be renewed each month until you cancel. You consent to Zookal automatically charging your payment method on file $19.99 each month after 1st month free period until you cancel.
How to Cancel
You can cancel your subscription anytime by visiting Manage account page, clicking "Manage subscription" and completing the steps to cancel. Cancellations take effect at the end of the 1st month free period (if applicable) or at the end of the current billing cycle in which your request to cancel was received. Subscription fees are not refundable.
Zookal Study Premium Monthly Subscription Includes:
Ability to post up to five (5) questions per month.
0% off your textbooks order and free standard shipping whenever you shop online at
textbooks.zookal.com.au
Unused monthly subscription benefits have no cash value, are not transferable, and expire at the end of each month. This means that subscription benefits do not roll over to or accumulate for use in subsequent months.
Payment Methods
Afterpay and Zip Pay will not be available for purchases with Zookal Study Premium subscription added to bag.
$1 preauthorisation
You may see a $1 preauthorisation by your bank which will disappear from your statement in a few business days..
Email communications
By adding Zookal Study Premium, you agree to receive email communications from Zookal.
The Guest Editors have assembled top key opinion leaders to provide current reviews on the multidisciplinary approach to the management of high-grade bladder cancer. Articles are devoted to fluorescence cystoscopy, confocal laser endomicroscopy, narrow band imaging; Novel therapeutic approaches for recurrent nonmuscle invasive bladder cancer; Trimodality therapy in bladder cancer; the data and the reality of perioperative chemotherapy in muscle invasive bladder cancer; radical transurethral resection alone, robotic or partial cystectomy or extended lymphadenectomy: Neoadjuvant paradigm for drug development in muscle invasive bladder cancer; Novel biomarkers to predict response and prognosis in localized bladder cancer; Immunotherapy in Advanced/Metastatic Urothelial Cancer ; and Adjuvant Chemotherapy in High Grade Upper Tract Urothelial Cancer.